Biostage, Inc. (BSTG)

OTCMKTS: BSTG · Delayed Price · USD
5.90
0.00 (0.00%)
Jan 12, 2023, 3:54 PM EST - Market closed
Market Cap 68.70M
Revenue (ttm) n/a
Net Income (ttm) -11.30M
Shares Out 11.64M
EPS (ttm) -1.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 671
Open 5.65
Previous Close 5.90
Day's Range 5.90 - 5.90
52-Week Range 3.30 - 9.00
Beta -0.92
Analysts Sell
Price Target n/a
Earnings Date Mar 28, 2023

About BSTG

Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company is engaged in developing Biostage Esophageal Implant for the treating esophageal cancer. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 6
Stock Exchange OTCMKTS
Ticker Symbol BSTG
Full Company Profile

Financial Performance

Financial Statements

News

Biostage Amends CEO Employment Agreement

Biostage removes Interim qualification from Mr. Green's title, making him Chief Executive Officer.

2 weeks ago - PRNewsWire

Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer

IQVIA was selected because of its dedicated gastrointestinal team and depth of experience in running cell-therapy clinical trials. HOLLISTON, Mass.

Other symbols: IQV
1 month ago - PRNewsWire

New Publication Demonstrates Rapid Esophageal Regeneration using the Biostage Esophageal Implant

Biostage expects to initiate patient recruitment in its first clinical trial in early 2023 HOLLISTON, Mass. , Dec. 23, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), ...

1 month ago - PRNewsWire

Biostage Reports Corporate Highlights and Third Quarter Financial Results

HOLLISTON, Mass. , Nov. 14, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating ...

2 months ago - PRNewsWire

Biostage Schedules Conference Call and Webcast for Q3 2022 Results

HOLLISTON, Mass. , Nov. 10, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treatin...

2 months ago - PRNewsWire

Biostage Receives U.S. Patent for Cellularized Patch-Based Scaffolds for Organ Repair

Extends core IP from tubes to patches and from regenerating the esophagus after esophagectomy to treating fistulas and strictures anywhere in the GI tract including the esophagus, stomach and intestin...

3 months ago - PRNewsWire

Biostage Announces Appointment of New Chief Financial Officer

HOLLISTON, Mass. , Aug. 8, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating e...

6 months ago - PRNewsWire

Biostage Reports Corporate Highlights and Second Quarter Financial Results

HOLLISTON, Mass. , Aug. 4, 2022 /PRNewswire/ --Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating es...

6 months ago - PRNewsWire

Biostage Schedules Conference Call and Webcast for Q2 2022 Results

HOLLISTON, Mass. , Aug. 4, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating...

6 months ago - PRNewsWire

Biostage Announces Publication of Mechanical Strength Data for Regenerated Esophageal Tissue in Journal of Biomechanics

The current study tested the biomechanical strength of the newly regenerated esophageal tissue and demonstrated that the strength of the tissue was comparable to adjacent native tissue. HOLLISTON, Mas...

8 months ago - PRNewsWire

Biostage Reports Q1 2022 Financial Results and Corporate Highlights

HOLLISTON, Mass. , May 16, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating...

9 months ago - PRNewsWire

Biostage Announces $5.1 Million Financing to Advance Clinical Trial

HOLLISTON, Mass. , May 13, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating e...

9 months ago - PRNewsWire

Biostage Schedules Conference Call and Webcast for Q1 2022 Results

HOLLISTON, Mass., May 10, 2022 /PRNewswire/ -- Biostage, Inc.  (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating...

9 months ago - PRNewsWire

Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneration and Repair of the Bronchus

Extends Core Intellectual Property coverage for treatment of lung cancer as well as esophageal cancer. HOLLISTON, Mass.

10 months ago - PRNewsWire

Biostage Reports Fourth Quarter and Fiscal Year 2021 Financial Results

HOLLISTON, Mass. , April 1, 2022 /PRNewswire/ -- Biostage, Inc.  (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treati...

10 months ago - PRNewsWire

Biostage Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2021 Financial Results

HOLLISTON, Mass. , March 30, 2022 /PRNewswire/ --  Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treat...

10 months ago - PRNewsWire

Biostage Announces "Meet the Founder, New Chairman and Interim CEO" Webinar

HOLLISTON, Mass., Jan. 25, 2022 /PRNewswire/ --  Biostage, Inc.  (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treati...

1 year ago - PRNewsWire

Biostage Announces Court's Preliminary Injunction Order Requiring its Insurance Carrier to Continue Paying for Defense

HOLLISTON, Mass., Jan. 25, 2022 /PRNewswire/ -- Biostage, Inc.  (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treatin...

1 year ago - PRNewsWire

New Paper Shows Biostage's Esophageal Implant Regenerates the Esophagus in Piglets

HOLLISTON, Mass., Jan. 10, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and...

1 year ago - PRNewsWire

Biostage Hires David Green as Chief Executive Officer

HOLLISTON, Mass., Nov. 30, 2021 /PRNewswire/ --  Biostage, Inc.  (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer a...

1 year ago - PRNewsWire

Biostage Reports Q3 2021 Financial Results

HOLLISTON, Mass., Nov. 15, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cell...

1 year ago - PRNewsWire

Biostage™ Appoints Jerry He to Board of Directors and Completes Private Placement of $2.6 Million to Continue Its Clinical Transition

HOLLISTON, Mass., Sept. 8, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing novel organ regeneration technology based its patented C...

1 year ago - PRNewsWire

Biostage Reports Q2 2021 Financial Results

HOLLISTON, Mass., Aug. 13, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cell...

1 year ago - PRNewsWire

Biostage Reports Q1 2021 Financial Results

HOLLISTON, Mass., May 24, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cellf...

1 year ago - PRNewsWire

Biostage Reports 2020 Financial Results and Appointment of Interim Vice President of Finance

HOLLISTON, Mass., April 13, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing next-generation bioengineered esophageal implants, today...

1 year ago - PRNewsWire